health
Evo2 raises sarcoma survival-model C-index estimates
A medRxiv preprint reports higher C-index estimates for several survival outcomes when Evo2-derived tumor-sequence features were added to existing risk models. The study analysed 102 patients with soft-tissue sarcoma and a separate 129-patient TCGA cohort; clinical use requires further validation.